# OnCo record nct04285086 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04285086/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04285086", "NCT04285086" ;
  schema:name "Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance"@en ;
  schema:alternateName "SURPASS ET"@en ;
  schema:description "A phase 3 trial of Ropeginterferon alfa-2b and Anagrelide in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04285086/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04285086> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2020-08-25" ;
  onco:cancers <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/cancers/essential-thrombocythaemia/> ;
  onco:technologies <https://onco.cc/technologies/cytokine-therapy/> ;
  onco:drugs <https://onco.cc/drugs/ropeginterferon-alfa-2b/>, <https://onco.cc/drugs/anagrelide/> ;
  onco:companies <https://onco.cc/companies/pharmaessentia/> .